

LAW OFFICES  
**KILYK & BOWERSOX, P.L.L.C.**  
*Intellectual Property Law*

RECEIVED  
**CENTRAL FAX CENTER**  
APR 08 2005

LUKE A. KILYK\* (PA, DC)  
LEONARD D. BOWERSOX  
JASBIR SINGH  
MATTHEW T. GILL  
RALPH T. WEBB\* (DC, TX, LA)  
SUSANNE M. HOPKINS  
J. MARK KONIECZNY\* (MA)

53 A East Lee Street  
WARRENTON, VA 20186

FAIRFAX OFFICE  
3603-E Chain Bridge Road  
Fairfax, Virginia 22030

TEL.: (540) 428-1701  
FAC.: (540) 428-1720  
(540) 428-1721

Email: lkilyk@kbpatentlaw.com  
Website: <http://www.kbpatentlaw.com>

Of Counsel:  
WILLIAM CHARLES JAMISON

\*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

**FACSIMILE TRANSMISSION COVER SHEET**

DATE: April 8, 2005

TO: Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/516,558  
Entitled: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE  
Our Ref.: 3190-070

FROM: Luke A. Kilyk, Esq. *JK*

FAC. TEL. NO.: 1-703-872-9306

**NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 12**

Items Attached: Supplemental Information Disclosure Statement -- 2 pages  
Form PTO 1449 -- 1 page  
Document -- 8 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 8, 2005.

Donald S. Prater  
Name (Print)

*Donald S. Prater*  
Signature

**THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED.** This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

APR 08 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 8, 2005.

Donald S. Prater  
Name (Print)

  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	Chano et al.	)	Examiner:	Unassigned
		)		
Application No.:	10/516,558	)	Group Art Unit:	Unassigned
		)		
Filed:	November 30, 2004	)	Confirmation No.:	Unassigned
		)		
Docket No.:	3190-070	)	Customer No.:	33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 8, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Supplemental Information Disclosure statement, then applicants respectfully petition under 37 C.F.R. § 1.97(c) to consider the documents set forth in the Supplemental Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and

Supplemental Information Disclosure Statement  
U.S. Patent Application No. 10/516,558


1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk  
Reg. No. 33,251

Atty. Docket No.: 3190-070  
KILYK & BOWERSOX, P.L.L.C.  
53 A East Lee Street  
Warrenton, VA 20186  
Tel.: (540) 428-1701  
Fax: (540) 428-1720  
Enclosures: PTO-1449, w/1 Document

Page 1 of 1

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-070	Application No. 10/516,558
<b>INFORMATION DISCLOSURE STATEMENT</b>	APPLICANT: CHANO et al.	Filing Date: November 30, 2004 Group Art Unit: Unassigned

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**